-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Since 2021, the domestic biomedical field has continued to raise a wave of financing, and it has not stopped at the end of the year
.
On the evening of December 7, Guizhou Bailing also issued an announcement stating that its subsidiary Chengdu Lingling successfully completed a round of financing of more than 100 million yuan.
The funds raised will help Chengdu Lingling to further optimize the shareholder structure and accelerate the promotion of Chengdu Lingling.
The new drug development process, strengthen the strength of the scientific research team, upgrade the level of scientific research equipment, enrich the research and development pipeline, and promote the rapid expansion of the company
.
This round of financing was led by the Sichuan Science and Technology Achievement Transformation Equity Investment Fund managed by Sichuan Venture Capital, Chengdu Biological City No.
1 Equity Investment Fund Partnership (Limited Partnership), Sichuan Academician Science and Technology Innovation Equity Investment Guidance Fund Partnership (Limited Partnership), Shenzhen Fuguo Wealth Venture Capital Partnership (Limited Partnership), Pengzhou Global Biomedical Technology Achievement Transformation Equity Investment Fund Partnership (Limited Partnership) and other funds and institutions followed up in the investment
.
According to the data, Chengdu Baoling has only two years since its establishment on April 29, 2019.
It is an enterprise specializing in the research and industrialization of innovative drugs.
The company’s shareholders are the team of Professor Lijuan Chen and Huaxi Health Technology, a wholly-owned subsidiary of West China Hospital of Sichuan University.
Co.
, Ltd.
and Guizhou Bailing Enterprise Group Pharmaceutical Co.
, Ltd.
are jointly constituted
.
It is worth mentioning that although it has not been established for a long time, Chengdu Lingling has a relatively powerful drug discovery and drug synthesis platform, a pharmacokinetic evaluation platform, an in vitro pharmacodynamics and target confirmation platform, and an in vivo pharmacodynamic evaluation platform.
With the help of these platform advantages, the company has continued to advance in scientific research and innovation in recent years.
At present, it has a total of 9 pipelines of innovative drug products under research, involving multiple pipelines such as malignant tumors, autoimmune diseases, neurological diseases, and digestive diseases.
Covers popular product areas such as small molecule drugs and ADC (antibody conjugated drugs)
.
From the perspective of progress, among them, the new class 1 chemical drug "Puisi mesylate for injection" for the treatment of hematological tumors has obtained the Chinese clinical trial notification and the US FDA clinical approval
.
The product invention patent has been authorized by 9 major countries and organizations in the world, covering more than 30 major countries in the world
.
This product is an HDAC inhibitor (histone deacetylation inhibitor).
Currently, the Phase I clinical trial jointly carried out by West China Hospital of Sichuan University and the Affiliated Hospital of Guizhou Medical University is nearing the end.
From the results of the completed trials, PM single The drug has reached the efficacy of first-line clinical treatment drugs, and the industry believes that the product has a promising future
.
The new class 1 chemical drug "flunotinib maleate tablets" for the treatment of myeloproliferative tumors (MPN) has also been notified of clinical trials in China
.
At present, the product has accumulatively applied for 27 invention patents, 21 of which have been authorized, including 7 Chinese patents.
The drug is a highly selective inhibitor with a clear target.
Preclinical studies have shown that the efficacy is better than that of drugs already on the market with the same target
.
In addition, ZL82, a new class 1 chemical drug of JAK3 highly selective inhibitor, is expected to submit a clinical trial application before the end of 2021, and is expected to be approved for clinical research in March-April 2022.
Its indications are internal rheumatoid arthritis and inflammation.
For sexual bowel disease, pre-clinical "head-to-head" trials have been carried out with the same target drug that has been marketed, and the efficacy is better than that of the marketed drug
.
In the next five years, Chengdu Zheling is expected to have a batch of Class 1 new drugs entering clinical research
.
.
On the evening of December 7, Guizhou Bailing also issued an announcement stating that its subsidiary Chengdu Lingling successfully completed a round of financing of more than 100 million yuan.
The funds raised will help Chengdu Lingling to further optimize the shareholder structure and accelerate the promotion of Chengdu Lingling.
The new drug development process, strengthen the strength of the scientific research team, upgrade the level of scientific research equipment, enrich the research and development pipeline, and promote the rapid expansion of the company
.
This round of financing was led by the Sichuan Science and Technology Achievement Transformation Equity Investment Fund managed by Sichuan Venture Capital, Chengdu Biological City No.
1 Equity Investment Fund Partnership (Limited Partnership), Sichuan Academician Science and Technology Innovation Equity Investment Guidance Fund Partnership (Limited Partnership), Shenzhen Fuguo Wealth Venture Capital Partnership (Limited Partnership), Pengzhou Global Biomedical Technology Achievement Transformation Equity Investment Fund Partnership (Limited Partnership) and other funds and institutions followed up in the investment
.
According to the data, Chengdu Baoling has only two years since its establishment on April 29, 2019.
It is an enterprise specializing in the research and industrialization of innovative drugs.
The company’s shareholders are the team of Professor Lijuan Chen and Huaxi Health Technology, a wholly-owned subsidiary of West China Hospital of Sichuan University.
Co.
, Ltd.
and Guizhou Bailing Enterprise Group Pharmaceutical Co.
, Ltd.
are jointly constituted
.
It is worth mentioning that although it has not been established for a long time, Chengdu Lingling has a relatively powerful drug discovery and drug synthesis platform, a pharmacokinetic evaluation platform, an in vitro pharmacodynamics and target confirmation platform, and an in vivo pharmacodynamic evaluation platform.
With the help of these platform advantages, the company has continued to advance in scientific research and innovation in recent years.
At present, it has a total of 9 pipelines of innovative drug products under research, involving multiple pipelines such as malignant tumors, autoimmune diseases, neurological diseases, and digestive diseases.
Covers popular product areas such as small molecule drugs and ADC (antibody conjugated drugs)
.
From the perspective of progress, among them, the new class 1 chemical drug "Puisi mesylate for injection" for the treatment of hematological tumors has obtained the Chinese clinical trial notification and the US FDA clinical approval
.
The product invention patent has been authorized by 9 major countries and organizations in the world, covering more than 30 major countries in the world
.
This product is an HDAC inhibitor (histone deacetylation inhibitor).
Currently, the Phase I clinical trial jointly carried out by West China Hospital of Sichuan University and the Affiliated Hospital of Guizhou Medical University is nearing the end.
From the results of the completed trials, PM single The drug has reached the efficacy of first-line clinical treatment drugs, and the industry believes that the product has a promising future
.
The new class 1 chemical drug "flunotinib maleate tablets" for the treatment of myeloproliferative tumors (MPN) has also been notified of clinical trials in China
.
At present, the product has accumulatively applied for 27 invention patents, 21 of which have been authorized, including 7 Chinese patents.
The drug is a highly selective inhibitor with a clear target.
Preclinical studies have shown that the efficacy is better than that of drugs already on the market with the same target
.
In addition, ZL82, a new class 1 chemical drug of JAK3 highly selective inhibitor, is expected to submit a clinical trial application before the end of 2021, and is expected to be approved for clinical research in March-April 2022.
Its indications are internal rheumatoid arthritis and inflammation.
For sexual bowel disease, pre-clinical "head-to-head" trials have been carried out with the same target drug that has been marketed, and the efficacy is better than that of the marketed drug
.
In the next five years, Chengdu Zheling is expected to have a batch of Class 1 new drugs entering clinical research
.
